Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis

INTRODUCTION: Adalimumab and etanercept are drugs used in anti-TNF therapy in patients with psoriasis and psoriatic arthritis. Despite the molecular targeting of these drugs, the loss of pharmacological response to treatment is observed in patients. The development of personalized medicine makes it possible to use not only clinical parameters of disease severity, but also molecular marker systems. AIM: expression profile may be a useful molecular marker of the therapeutic potential of anti-TNF drugs. MATERIAL AND METHODS: α expression was evaluated at the transcriptome and proteome levels using the RT-qPCR method (transcriptional activity assay) and MALDI-TOF MS (protein level assessment). RESULTS: Depending on the drug, different expression profiles of the studied cytokines are observed. CONCLUSIONS: may be useful markers of the efficacy of anti-TNF therapy, thus complementing clinical parameters.